Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 202,422	$ 541,835
Available for sale securities	131,545	0
Accounts receivable, net of allowances of approximately $3.0 million and $2.9 million at June 30, 2017 and December 31, 2016, respectively	15,570	22,087
Inventory, net	71,417	70,898
Prepaid expenses and other current assets	15,074	19,133
Total current assets	436,028	653,953
Fixed assets, net	20,899	30,961
Indefinite-lived intangible assets	188,620	253,620
Finite-lived intangible assets, net	100,451	361,601
Goodwill	255,629	255,629
Restricted cash	5,033	5,032
Contingent purchase price from sale of businesses	143,700	143,700
Other assets	749	715
Total assets	1,151,109	1,705,211
Current liabilities:
Accounts payable	16,531	28,450
Accrued expenses	87,384	88,524
Current portion of contingent purchase price	66,700	55,000
Convertible senior notes	330,637	53,749
Deferred revenue	14,039	18,902
Total current liabilities	515,291	244,625
Contingent purchase price	44,471	82,289
Convertible senior notes	305,517	623,584
Deferred tax liabilities	67,003	89,992
Other liabilities	13,821	11,705
Total liabilities	946,103	1,052,195
Equity component of currently redeemable convertible senior notes	62,053	1,033
Stockholders’ equity:
Preferred stock, $1.00 par value per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value per share, 187,500,000 authorized; 75,599,584 issued and 72,586,441 outstanding at June 30, 2017 and 73,212,545 issued and 71,019,563 outstanding at December 31, 2016	76	73
Additional paid-in capital	1,287,260	1,256,890
Treasury stock, at cost; 3,013,143 and 2,192,982 shares at June 30, 2017 and December 31, 2016, respectively	(90,016)	(50,000)
Accumulated deficit	(1,048,921)	(548,983)
Accumulated other comprehensive loss	(5,446)	(5,479)
Total The Medicines Company stockholders’ equity	142,953	652,501
Non-controlling interest in joint venture	0	(518)
Total stockholders’ equity	142,953	651,983
Total liabilities and stockholders’ equity	1,151,109	1,705,211
Product licenses, net
Current assets:
Finite-lived intangible assets, net	0	26,987
Developed product rights, net
Current assets:
Finite-lived intangible assets, net	100,451	334,614
In-process research & development
Current assets:
Indefinite-lived intangible assets	$ 188,620	$ 253,620